Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Centessa Pharmaceuticals plc CNTA

Healthcare Biotechnology
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as... see more

Current News (NDAQ:CNTA)

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire 12 days ago

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

GlobeNewswire January 14, 2026

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications 

GlobeNewswire December 11, 2025

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

GlobeNewswire November 11, 2025

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

GlobeNewswire November 11, 2025

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2025

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

GlobeNewswire November 5, 2025

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

GlobeNewswire September 3, 2025

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

GlobeNewswire August 12, 2025
View More News ››

Opinion & Analysis (NDAQ:CNTA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CNTA)

Be the first to post on this bullboard.

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp. engages in the acquisition and exploration of mineral properties in the natural resource sector in ...
View More »

Podcasts